EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Staph wars: the antibiotic pipeline strikes back

Edward J A Douglas, Maisem Laabei

Microbiology · 01.09.2023 · 169 (9)

DOI: 10.1099/mic.0.001387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbiology, erschienen am 01.09.2023. Verfasst von Edward J A Douglas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Bath, Bath BA2 7AY, UK. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Anti-Infective Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 288 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic chemotherapy is widely regarded as one of the most significant medical advancements in history. However, the continued misuse of antibiotics has contributed to the rapid rise of antimicrobial resistance (AMR) globally. Staphylococcus aureus , a major human pathogen, has become synonymous with multidrug resistance and is a leading antimicrobial-resistant pathogen causing significant morbidity and mortality worldwide. This review focuses on (1) the targets of current anti-staphylococcal antibiotics and the specific mechanisms that confirm resistance; (2) an in-depth analysis of recently licensed antibiotics approved for the treatment of S. aureus infections; and (3) an examination of the pre-clinical pipeline of anti-staphylococcal compounds. In addition, we examine the molecular mechanism of action of novel antimicrobials and derivatives of existing classes of antibiotics, collate data on the emergence of resistance to new compounds and provide an overview of key data from clinical trials evaluating anti-staphylococcal compounds. We present several successful cases in the development of alternative forms of existing antibiotics that have activity against multidrug-resistant S. aureus . Pre-clinical antimicrobials show promise, but more focus and funding are required to develop novel classes of compounds that can curtail the spread of and sustainably control antimicrobial-resistant S. aureus infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnti-Infective AgentsHumansAnti-Bacterial AgentsStaphylococcus aureusStaphylococcusMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Staphylococcus aureusantibiotic therapyantimicrobial resistance

Substanzen

Anti-Bacterial AgentsAnti-Infective Agents

Autor:innen und Institutionen

  • Department of Life Sciences, University of Bath, Bath BA2 7AY, UK.

Förderung

  • Academy of Medical Sciences

Zitieren

APA

Douglas, E. J. A., & Laabei, M. (2023). Staph wars: the antibiotic pipeline strikes back. Microbiology, 169(9). https://doi.org/10.1099/mic.0.001387

Vancouver

Douglas EJA, Laabei M. Staph wars: the antibiotic pipeline strikes back. Microbiology. 2023;169(9). doi:10.1099/mic.0.001387

BibTeX
@article{Douglas2023,
  author = {Douglas, Edward J A and Laabei, Maisem},
  title = {Staph wars: the antibiotic pipeline strikes back},
  journal = {Microbiology},
  year = {2023},
  volume = {169},
  number = {9},
  doi = {10.1099/mic.0.001387}
}
Kostenlos starten →